Galactose cluster-pharmacokinetic modulator targeting moiety for siRNA

US9796756B2 · kind B2 · utility

Assignee

• Arrowhead Pharmaceuticals, Inc. · US

Inventors

• Philipp Hadwiger · Kulmbach, DE
• Torsten Hoffmann · Weil am Rhein, DE
• Eric A. Kitas · Aesch, CH
• Peter Mohr · Basel, CH
• Ingo Roehl · Memmelsdorf, DE
• Linda Valis · Bamberg, DE
• David B. Rozema · Madison, US
• David L. Lewis · Madison, US
• Darren H. Wakefield · Fitchburg, US

Key dates

• Filing date: Dec 17, 2015
• Grant date: Oct 24, 2017
• Expiry date: Dec 17, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07H21/02
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to cell in vivo. The pharmacokinetic modulator improve in vivo targeting compared to the targeting ligand alone. Targeting ligand-pharmacokinetic modulator targeting moiety targeted RNAi polynucleotides can be administered in vivo alone or together with co-targeted delivery polymers.